Evaxion A/S (EVAX) stock
EVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 5, 2026Score 2/30
$2.54−0.24 (-8.63%)
Close on Nov 18, 2026Market cap $21.18MP/E –Yield –
Evaxion A/S operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Evaxion A/S's operating income for the twelve months ending Jun 30, 2022 was -$26.29M. For fiscal 2025 it was -$9.23M. The highest annual figure on record is -$5.63M in fiscal 2018.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$9.23M | – |
| FY2024 | Dec 31, 2024 | -$14.73M | – |
| FY2023 | Dec 31, 2023 | -$22.20M | – |
| FY2022 | Dec 31, 2022 | -$25.26M | – |
| FY2021 | Dec 31, 2021 | -$25.83M | – |
| FY2020 | Dec 31, 2020 | -$16.57M | – |
| FY2019 | Dec 31, 2019 | -$10.86M | – |
| FY2018 | Dec 31, 2018 | -$5.63M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.85M | – |
| Q2 FY2025 | Jun 30, 2025 | -$4.34M | – |
| Q2 FY2024 | Jun 30, 2024 | -$4.58M | – |
| Q2 FY2023 | Jun 30, 2023 | -$5.68M | – |
| Q2 FY2022 | Jun 30, 2022 | -$6.26M | – |
| Q1 FY2022 | Mar 31, 2022 | -$6.40M | – |
| Q4 FY2021 | Dec 31, 2021 | -$7.72M | – |
| Q3 FY2021 | Sep 30, 2021 | -$5.91M | – |
| Q2 FY2021 | Jun 30, 2021 | -$7.03M | – |
| Q1 FY2021 | Mar 31, 2021 | -$5.18M | – |
| Q4 FY2020 | Dec 31, 2020 | -$4.65M | – |
| Q3 FY2020 | Sep 30, 2020 | -$4.69M | – |
| Q2 FY2020 | Jun 30, 2020 | -$3.94M | – |
| Q1 FY2020 | Mar 31, 2020 | -$3.29M | – |
See a number that looks wrong?